HLS Therapeutics Inc. 74D.F Stock
HLS Therapeutics Inc. Price Chart
HLS Therapeutics Inc. 74D.F Financial and Trading Overview
| HLS Therapeutics Inc. stock price | 2.6 EUR |
| Previous Close | 3.98 EUR |
| Open | 4.32 EUR |
| Bid | 4.3 EUR x N/A |
| Ask | 4.52 EUR x N/A |
| Day's Range | 4.32 - 4.32 EUR |
| 52 Week Range | 2.72 - 9.75 EUR |
| Volume | 300 EUR |
| Avg. Volume | 5 EUR |
| Market Cap | 181.01M EUR |
| Beta (5Y Monthly) | 0.969215 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.79 EUR |
| Forward Dividend & Yield | 0.13 (3.32%) |
| Ex-Dividend Date | April 27, 2023 |
| 1y Target Est | N/A |
74D.F Valuation Measures
| Enterprise Value | 204.68M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.9352643 |
| Price/Book (mrq) | 1.1755103 |
| Enterprise Value/Revenue | 3.319 |
| Enterprise Value/EBITDA | 10.27 |
Trading Information
HLS Therapeutics Inc. Stock Price History
| Beta (5Y Monthly) | 0.969215 |
| 52-Week Change | -52.62% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.75 EUR |
| 52 Week Low | 2.72 EUR |
| 50-Day Moving Average | 3.53 EUR |
| 200-Day Moving Average | 5.85 EUR |
74D.F Share Statistics
| Avg. Volume (3 month) | 5 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 32.35M |
| Float | 14.52M |
| Short Ratio | N/A |
| % Held by Insiders | 6.16% |
| % Held by Institutions | 67.67% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.145 |
| Trailing Annual Dividend Yield | 3.64% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -41.79% |
| Operating Margin (ttm) | -22.37% |
| Gross Margin | 82.16% |
| EBITDA Margin | 32.31% |
Management Effectiveness
| Return on Assets (ttm) | -3.41% |
| Return on Equity (ttm) | -18.54% |
Income Statement
| Revenue (ttm) | 61.67M EUR |
| Revenue Per Share (ttm) | 1.9 EUR |
| Quarterly Revenue Growth (yoy) | 1.40% |
| Gross Profit (ttm) | 50.76M EUR |
| EBITDA | 19.93M EUR |
| Net Income Avi to Common (ttm) | -25774000 EUR |
| Diluted EPS (ttm) | -0.6 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 21.21M EUR |
| Total Cash Per Share (mrq) | 0.66 EUR |
| Total Debt (mrq) | 95.2M EUR |
| Total Debt/Equity (mrq) | 80.07 EUR |
| Current Ratio (mrq) | 1.482 |
| Book Value Per Share (mrq) | 3.675 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 15.2M EUR |
| Levered Free Cash Flow (ttm) | 14.27M EUR |
Profile of HLS Therapeutics Inc.
| Country | Germany |
| State | ON |
| City | Etobicoke |
| Address | 10 Carlson Court |
| ZIP | M9W 6L2 |
| Phone | 647-495-9000 |
| Website | https://www.hlstherapeutics.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 99 |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the United States marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Q&A For HLS Therapeutics Inc. Stock
What is a current 74D.F stock price?
HLS Therapeutics Inc. 74D.F stock price today per share is 2.6 EUR.
How to purchase HLS Therapeutics Inc. stock?
You can buy 74D.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for HLS Therapeutics Inc.?
The stock symbol or ticker of HLS Therapeutics Inc. is 74D.F.
Which industry does the HLS Therapeutics Inc. company belong to?
The HLS Therapeutics Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does HLS Therapeutics Inc. have in circulation?
The max supply of HLS Therapeutics Inc. shares is 32.58M.
What is HLS Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
HLS Therapeutics Inc. PE Ratio is now.
What was HLS Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
HLS Therapeutics Inc. EPS is -0.79 EUR over the trailing 12 months.
Which sector does the HLS Therapeutics Inc. company belong to?
The HLS Therapeutics Inc. sector is Healthcare.